Binding of latent matrix metalloproteinase 9 to fibrin: Activation via a plasmin-dependent pathway

Inflammation

Volumn 22, Issue 3, 1998, Pages 287-305

  Makowski, Gregory S ^a   Ramsby, Melinda L ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; FIBRIN; FIBRONECTIN; GELATINASE A; GELATINASE B; PLASMIN; PROCOAGULANT;

ARTICLE; BASEMENT MEMBRANE; CALIBRATION; CANCER INVASION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DENSITOMETRY; ENZYME BINDING; EXTRACELLULAR MATRIX; FIBRINOLYSIS; INFLAMMATION; METASTASIS; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

COLLAGENASES; ENZYME ACTIVATION; FIBRIN; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MOLECULAR WEIGHT; NEUTROPHILS; PLASMIN; TIME FACTORS; TISSUE EXTRACTS;

EID: 0031860311     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022300216202     Document Type: Article

References (74)

1. WOESSNER, J. F., JR. 1994. The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci. 731:11-21.
2. NAGASE, H. 1996. Matrix metalloproteinases. In: Zinc Metalloproteinases in Health and Disease, N. M. Hooper, ed. Taylor and Francis, London. England, pp. 153-204.
3. STETLER-STEVENSON, W. G., S. AZNAVOORIAN, and L. S. LIOTTA. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann. Rev. Cell Biol. 9:541-573.
4. CLIFFTON, E. E., and D. AGOSTINO. 1965. The effects of fibrin formation and alterations in the clotting mechanism on the development of metastases. Vasc. Dis. 2:43-52.
5. DVORAK, H. F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl. J. Med. 315:1650-1659.
6. WYSOCKI, A. B., L. STAIANO-COICO, and F. GRINNELL. 1993. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J. Invest. Dermatol. 101:64-68.
7. MIGNATTI, P., and D. B. RIFKIN. 1996. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enz. Prot. 49:117-137.
8. DECLERCK, Y. A., and W. E. LAUG. 1996. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. Enz. Prot. 49:72-84.
9. RICKLES, F. R., and R. L. EDWARDS. 1983. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62:14-31.
10. EGYUD, L. G., and B. LIPINSKI. 1991. Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer. Med. Hypoth, 36:336-340.
11. TRYGGVASON, K., M. HOYHTYA, and T. SALO. 1987. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta. 907:191-217.
12. MIGNATTI, P., and D. B. RIFKIN. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:161-195.
13. KOOLWIJK, P. A., M. M. MILTENBURG, M. G. M. VAN ERCK, M. OUDSHOORN, M. J. NIEDBALA, F. C. BREEDVELD, and V. W. M. VAN HINSBERGH. 1995. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variable of inflammation. J. Rheumatol. 22:385-393.
14. BROWN, D. L., M. S. HIBBS, M. KEARNEY, C. LOUSHIN, and J. M. ISNER. 1995. Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions. Circulation 91:2125-2131.
15. VAN WART, H. E., and H. BIRKEDAL-HANSEN. 1990. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U.S.A. 87:5578-5582.
16. NAGASE, H. 1997. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378:151-160.
17. MAZZIERI, R., L. MASIERO, L. ZANETTA, S. MONEA, M. ONISTO, S. GARBISA, and P. MIGNATTI. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332.
18. GINESTRA, A., S. MONEA, G. SEGHEZZI, V. DOLO, H. NAGASE, P. MIGNATTI, and M. L. VITTORELLI. 1997. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272:17216-17222.
19. RAKOCZI, I., B. WIMAN, and D. COLLEN. 1978. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim. Biophys. Acta. 540:295-300.
20. LIOTTA, L. A., R. H. GOLDFARB, R. BRUNDAGE, G. P. SIEGAL, V. TERRANOVA, and S. GARBISA. 1981. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41:4629-4636.
21. PEPPER, M. S., A. P. SAPPINO, R. STOCKLIN, R. MONTESANO, L. ORCI, and J. D. VASSALLI. 1993. Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. 122:673-684.
22. HOYLAERTS, M., D. C. RIJKEN, H. R. LIJNEN, and D. COLLEN. 1982. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J. Biol. Chem. 257:2912-2919.
23. BLASI, F., M. P. STOPPELLI, and M. V. CUBELLIS. 1986. The receptor for urokinase plasminogen activator. J. Cell Biochem. 32:179-186.
24. BLASI, F., J-D. VASSALLI, and K. DANO. 1987. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 104:801-804.
25. MOSCATELLI, D., and D. B. RIFKIN. 1988. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim. Biophys. Acta 948:67-85.
26. 3. Cell 85:683-693.
27. MONSKY, W. L., T. KELLY, C. Y. LIN, Y. YEH, W. G. STETLER-STEVENSON, S. C. MUELLER, and W. T. CHEN. 1993. Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res. 53:3159-3164.
28. MURPHY, G., F. WILLENBOCK, R. V. WARD, M. I. CROCKETT, D. EATON, and A. J. DOCHERTY. 1992. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem. J. 283:637-641.
29. OKADA, Y., J. P. BELLOCQ, N. ROUYER, M. P. CHENARD, M. C. RIO, P. CHAMBON, and P. BASSET. 1995. Membrane-type metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, head and neck carcinomas. Proc. Natl. Acad. Sci. U.S.A. 92:2730-2734.
30. SATO, H., T. TAKINO, Y. OKADA, J. CAO, A. SHINAGAWA, E. YAMAMOTO, and M. SEIKI. 1994. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370:61-65.
31. STATHAKIS, N. E., M. W. MOSESSON, A. B. CHEN, and D. K. GALANAKIS. 1978. Cryoprecipitation of fibrin-fibrinogen complexes induced by the cold-insoluble globulin of plasma. Blood 51:1211-1222.
32. HIBBS, M. S., K. A. HASTY, J. M. SEYER, A. H. KANG, and C. L. MAINARDI. 1985. Biochemical and immunological characterization of the secreted forms of neutrophil gelatinase. J. Biol. Chem. 260:2493-2500.
33. VARTIO, T., and M. BAUMANN. 1989. Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett. 255:285-289.
34. MAKOWSKI, G. S., and M. L. RAMSBY. 1996. Calibrating gelatin zymograms with human gelatinase standards. Anal. Biochem. 236:353-356.
35. BODDEN, M. K., G. J. HARBER, B. BIRKEDAL-HANSEN, L. J. WINDSOR, N. C. M. CATERINA, J. A. ENGLER, and H. BIRKEDAL-HANSEN. 1994. Functional domains of human TIMP-1 (tissue inhibitor of metalloproteinases). J. Biol. Chem. 269:18943-18952.
36. 2 production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. Meth. Enzymol. 105:358-365.
37. CLAUSS, A. 1957. Rapid physiological coagulation method for the determination of fibrinogen. Acta. Haematol. 17:237-246.
38. REGOECZI, E. 1968. Occlusion of plasma proteins by human fibrin: studies using trace-labelled proteins. Br. J. Haematol. 14:279-290.
39. LAEMMLI, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
40. HEUSSEN, C., and E. B. DOWDLE. 1980. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 102:196-202.
41. MAKOWSKI, G. S., and M. L. RAMSBY. 1993. pH modification to enhance the molecular seiving properties of sodium dodecyl sulfate-10% polyacrylamide gels. Anal. Biochem. 212:283-285.
42. LUCAS, M. A., L. J. FRETTO, and P. A. MCKEE. 1983. Binding of human plasminogen to fibrin and fibrinogen. J. Biol. Chem. 258:4249-4256.
43. FRANCIS, C. W., V. J. MARDER, and G. H. BARLOW. 1980. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. J. Clin. Invest. 66:1033-1043.
44. FEARNLEY, G. R., and J. M. TWEED. 1952. Evidence of an active fibrinolytic enzyme in the plasma of normal people with observation on inhibition associated with the presence of calcium. Clin. Sci. 1953; 12:81-89.
45. CHAKRABARTI, R., M. BIELAWIEC, J. F. EVANS, and G. R. FEARNLEY. 1968. Methodological study and a recommended technique for determining the euglobulin lysis time. J. Clin. Pathol. 21:698-701.
46. GOLDBERG, G. I., B. L. MARMER, G. A. GRANT, A. Z. EISEN, S. WILHELM, and C. HE. 1989. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloprotease designated TIMP-2. Proc. Natl. Acad. Sci. U.S.A. 86:8207-8211.
47. MURPHY, G., and T. CRABBE. 1995. Gelatinases A and B. Meth. Enzymol. 248:470-484.
48. STRONGIN, A., I. COLLIER, P. KRASNOV, L. TERESA GENRICH, B. MARMER, and G. GOLDBERG. 1993. Human 92 kDa type IV collagenase: functional analysis of fibronectin and carboxyl-end domains. Kidney Intl. 43:158-162.
49. PREISSNER, K. T. 1989. The role of vitronectin as multifunctional regulator in the hemostatic and immune systems. Blut 59:419-431.
50. MIRSHAHI, M., J. SORIA, H. LU, C. SORIA, M. SAMAMA, and J. P. CAEN. 1988. Defective thrombolysis due to collagen incorporation in fibrin clots. Thromb. Res. 58:73-80.
51. GRINNELL, F., M. FELD, and D. MINTER. 1980. Fibroblast adhesion to fibrinogen and fibrin substrata: requirement for cold-insoluble globulin (plasma fibronectin). Cell 19:517-525.
52. STEFFEN, L. W., and B. W. STEFFEN. 1976. Improved method for measuring fibrinogen in plasma, with use of a plasmin inhibitor. Clin. Chem. 22:381-383.
53. RICHARDSON, D. L., D. S. PEPPER, and A. B. KAY. 1976. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br. J. Haematol. 32:507-513.
54. WACHTFOGEL, Y. T., W. ABRAMS, U. KUCICH, G. WEINBAUM, M. SCHAPIRA, and R. W. COLMAN. 1988. Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate human neutrophil degranulation. J. Clin. Invest. 81:1310-1316.
55. ROWLAND, F. N., M. J. DONOVAN, P. T. PICCIANO, G. D. WILNER, and D. L. KREUTZER. 1984. Fibrin-mediated vascular injury: identification of fibrin peptides that mediate endothelial cell retraction. J. Pathol. 117:P418-428.
56. RAMSBY, M. L., and D. L. KREUTZER. 1993. Fibrin induction of tissue plasminogen activator in corneal endothelial cells in vitro. Invest. Ophthalmol. Vis. Sci. 34:3207-3219.
57. RAMSBY, M. L., and D. L. KREUTZER. 1993. Fibrin induction of thrombospondin in corneal endothelial cell in vitro. Invest. Ophthalmol. Vis. Sci. 34:165-174.
58. RAMSBY, M. L., and D. L. KREUTZER. 1994. Fibrin induction of interleukin-8 (IL-8) in corneal endothelial cell in vitro. Invest. Ophthalmol. Vis. Sci. 35:3980-3990.
59. SALO, T., M. MAKELA, M. KYLMANIEMI, H. AUTIO-HARMAINEN, and H. LARJAVA. 1994. Expression of matrix metalloproteinase-2 and -9 during early wound healing. Lab. Invest. 70:176-182.
60. MATSUBARA, M., M. T. GIRARD, C. L. KUBLIN, C. CINTRON, and M. E. FINI. 1991. Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodelling cornea. Dev. Biol. 147:425-439.
61. BROWN, L. F., A. M. DVORAK, and H. F. DVORAK. 1989. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and many other types of disease. Am. Rev. Respir. Dis. 140:1104-1107.
62. GALIS, Z. S., G. K. SUKOVA, M. W. LARK, and P. LIBBY. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493-2503.
63. YOUNG, P. K., and F. GRINNELL. 1994. Metalloproteinase activation cascade after burn injury: a longitudinal analysis of the human wound environment. J. Invest. Dermatol. 103:660-664.
64. COLLIER, I. E., S. M. WILHELM, A. Z. EISEN, B. L. MARMER, G. A. GRANT, J. L. SELTZER, A. KRONBERGER, C. HE, E. BAUER, and G. I. GOLDBERG. 1988. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J. Biol. Chem. 263:6579-6587.
65. KESKI-OJA, J., J. LOHI, A. TUUTTILA, K. TRYGGVASON, and T. VARTIO. 1992. Proteolytic processing of the 72,000-Da type-IV collagenase by urokinase plasminogen activator. Exp. Cell Res. 202:471-476.
66. MORODOMI, T., Y. OGATA, Y. SASAGURI, M. MORIMATSU, and H. NAGASE. 1992. Purification and characterization of matrix metalloproteinase-9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem. J. 285:603-611.
67. OKADA, Y., T. MORODOMI, J. J. ENGHILD, K. SUZUKI, A. YASUI, I. NAKANISHI, G. SALVESEN, and H. NAGASE. 1990. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur. J. Biochem. 194:721-730.
68. LIJNEN, H. R., and D. COLLEN. 1982. Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Sem. Thromb. Hemost. 8:2-10.
69. MURPHY, G., S. ATKINSON, R. WARD, J. GAVRILOVIC, and J. J. REYNOLD. 1992. The role of plasminogen activators in the regulation of connective tissue metallproteinases. Ann. N. Y. Acad. Sci. 667:1-12.
70. DVORAK, H. F., D. R. SENGER, and A. M. DVORAK. 1983. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metast. Rev. 2:41-73.
71. DVORAK, H. F., A. M. DVORAK, E. J. MANSEAU, L. WIBERG, and W. H. CHURCHILL. 1979. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J. Natl. Cancer Inst. 62:1459-1472.
72. NAGY, J. A., L. F. BROWN, D. R. SENGER, N. LANIR, L. VAN DE WATER, A. M. DVORAK, and H. F. DVORAK. 1988. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta. 948:305-326.
73. CARDINALI, M., R. UCHINO, and S. I. CHUNG. 1990. Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymophine-activated killer cells. Cancer Res. 50:8010-8016.
74. FESUS, L., and K. LAKI. 1976. On coupling bovine fibrinogen to the surface of malignant murine plasma cells by means of transglutaminase. Biochem. Biophys. Res. Comm. 72:131-137.